Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ALMR

Alamar Biosciences Inc

May 29 • 04:00PM ET

20.44

+0.68 3.44 %

Healthcare • Medical Devices • USA • Small • NASD

Peers: INMD IRTC MASI BSX EW MDT BAX TFX BDX RMD

| Held by: ARKG VTI VXF VTWO LFSC VTWG VTWV VTHR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	45.33%	Shs Outstand	69.31M	Perf Week	-7.09%
Market Cap	1.42B	Forward P/E	-	EPS next Y	-0.66	Insider Trans	1.52%	Shs Float	37.89M	Perf Month	-16.50%
Enterprise Value	1.69B	PEG	-	EPS next Q	-1.71	Inst Own	-	Short Float	4.49%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	-560.71%	Inst Trans	16.77%	Short Ratio	3.72	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	52.25%	ROA	-	Short Interest	1.70M	Perf YTD	-7.09%
Book/sh	-2.57	P/C	21.93	EPS next 5Y	-28.20%	ROE	-	52W High	27.20 -24.85%	Perf Year	-
Cash/sh	0.93	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	18.84 8.46%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.56% 7.37%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.53	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.68	EPS Q/Q	-	SMA20	-7.27%	Beta	-	Target Price	30.75
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-10.32%	Rel Volume	0.86	Prev Close	19.76
Employees	222	LT Debt/Eq	-	Earnings	May 08 BMO	SMA200	-10.32%	Avg Volume	456.44K	Price	20.44
IPO	Apr 17, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	401,927	Change	3.44%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	TD Cowen	Buy	$30
May-12-26	Initiated	Stifel	Buy	$28
May-12-26	Initiated	Leerink Partners	Outperform	$35
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	BofA Securities	Neutral	$27

May-12-26 09:56AM	Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls (The Fly)
May-08-26 08:00AM	Alamar Biosciences Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:05PM	Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference (GlobeNewswire)
Apr-19-26 10:41PM	Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ (PR Newswire)

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

Co-FounderDr. Yuling Luo Ph.D.

Co-FounderDr. Shiping Chen Ph.D.

Chief Financial OfficerMr. Justin J. McAnear

PresidentMr. Timothy Ogden White J.D.

FounderMs. Yiyuan Yin Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Illumina Innovation Fund II GP	10% Owner	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:45 PM
Naclerio Nicholas	Director	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMR

Alamar Biosciences Inc

Upgrade your Finviz experience